Nota
Infección del torrente sanguíneo por Candida glabrata en una unidad de cuidados intensivos neonatales con prescripción de profilaxis con fluconazolBloodstream infections with Candida glabrata in a neonatal intensive care unit that uses prophylaxis with fluconazole

https://doi.org/10.1016/j.riam.2020.06.002Get rights and content

Resumen

Antecedentes

Candida glabrata es un patógeno emergente con capacidad de desarrollar tolerancia y resistencia a los antifúngicos azólicos, lo que genera incertidumbre sobre la utilidad de la profilaxis antifúngica en recién nacidos.

Objetivos

El objetivo de este estudio fue describir los factores asociados a la infección por C. glabrata en una UCIN que utiliza la profilaxis con fluconazol.

Métodos

Se diseñó un estudio de casos y controles pareado por edad gestacional realizado en el Hospital Civil de Guadalajara Dr. Juan I. Menchaca. Se estudiaron los recién nacidos con infección por C. glabrata y para cada uno se seleccionó un control pareado por edad gestacional; se estimaron razones de momios (RM) con intervalos de confianza del 95% (IC 95%) y prueba de McNemar para contraste de hipótesis.

Resultados

Veintiún pacientes presentaron infección, con el 66,7% de ellos de género masculino; la mediana de edad gestacional fue de 31,5 semanas. Se observó mayor riesgo de infección por C. glabrata cuando hubo prescripción de más de un esquema antimicrobiano (RM 21, IC 95% 1,23 - 358,3; p = 0,006) y en pacientes con comorbilidades quirúrgicas (RM 8, IC 95% 1,01 - 63,9; p = 0,04). Durante el periodo de estudio el riesgo de infección no se vio aumentado por la exposición a fluconazol.

Conclusiones

Presentaron mayor riesgo de infección por C. glabrata los neonatos con más de un esquema antimicrobiano y aquellos con comorbilidades quirúrgicas.

Abstract

Background

Candida glabrata is an emerging pathogen with the ability to develop tolerance and resistance to azole antifungals, which creates uncertainty about the usefulness of antifungal prophylaxis in newborns.

Aims

The aim of this study was to describe the factors associated with C. glabrata infection in a NICU that uses prophylaxis with fluconazole.

Methods

A case-control study paired by gestational age was designed and conducted at the Civil Hospital of Guadalajara Dr. Juan I. Menchaca. Newborns with C. glabrata infection were studied and for each one a matched control was selected by gestational age. Odds ratios (OR) were estimated with 95% confidence intervals (95% CI) and McNemar test for contrast of hypothesis was applied.

Results

Twenty-one infected patients were identified, from whom 66.7% were male; the median gestational age was 31.5 weeks. Increased risk of infection with C. glabrata was observed when there was a prescription of more than one antimicrobial scheme (OR 21, 95% CI, 1.23 - 358.3; p = 0.006) and also among patients with surgical comorbidities (OR 8, 95% CI 1.01 - 63.9; p = 0.04). During the study period, exposure to fluconazole showed no difference in the risk of infection.

Conclusions

Neonates with more than one antimicrobial regimen and those with surgical comorbidities had a higher risk of C. glabrata infection.

Bibliografía (16)

  • G.W. Jeon et al.

    Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks’ gestation

    J Formos Med Assoc.

    (2014)
  • M.E. Santolaya et al.

    Recommendations for the management of candidemia in neonates in Latin America. Grupo Proyecto Épico

    Rev Iberoam Micol.

    (2013)
  • S.B. Ascher et al.

    Antifungal therapy and outcomes in infants with invasive Candida infections

    Pediatr Infect Dis J.

    (2012)
  • A. Auron et al.

    Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants

    Pediatr Nephrol.

    (2009)
  • R. Beyer et al.

    Antifungal susceptibility of yeast bloodstream isolates collected during a 10-year period in Austria

    Mycoses.

    (2019)
  • E. Castagnola et al.

    Combined antifungal therapy for persistent central venous catheter-related candidemia in extremely low birth weight neonates

    J Chemother.

    (2009)
  • L. Clerihew et al.

    Antifungal therapy for newborn infants with invasive fungal infection

    Cochrane Database Syst Rev.

    (2012)
  • Consejo de Salubridad General. Prevención, diagnóstico y tratamiento de sepsis y choque séptico del recién nacido en el...
There are more references available in the full text version of this article.

Cited by (3)

  • Candida glabrata is a successful pathogen: An artist manipulating the immune response

    2022, Microbiological Research
    Citation Excerpt :

    Aus1p is the sterol transporter responsible for lowering azole susceptibility in the presence of serum and protecting C. glabrata against azole toxicity (Nakayama et al., 2007). The ability of yeast to generate resistance to some antifungal drugs and the treatment of previous infections due to candidiasis associated with other species, such as C. albicans, could be determining factors in the resistance of C. glabrata (Garnacho-Montero et al., 2010; Lee et al., 2010; Lona-Reyes et al., 2020). These drug-resistance mechanisms increase the virulence of C. glabrata and constitute another exceptional characteristic of this yeast.

View full text